Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 516-523

  Chen, Tzu Ping ^a   Chen, Chien Ming ^b   Chang, Hsueh Wen ^b   Wang, Jyh seng ^c   Chang, Wei Chi ^d   Hsu, Su In ^d   Cho, Chung Lung ^b  

^a E DA HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d Gao bo Pathology Laboratory   (Taiwan)

Author keywords

Cervical neoplasm; p27; Phospho MAPK ERK1 2; Progression; SKP2

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM STAGING; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 33846939567     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.015     Document Type: Article

References (40)

1. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 (1995) 682-685
2. Spruck C., Strohmaier H., Watson M., Smith A.P., Ryan A., Krek TW., et al. A CDK-independent function of mammalian Cks1: targeting of SCF(SKP2) to the CDK inhibitor p27Kip1. Mol. Cell 7 (2001) 639-650
3. Skp2 complex through phosphorylated in p27. Curr. Biol. 9 (1999) 661-664
4. Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J., et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5043-5048
5. Fero M.L., Rivkin M., Tasch M., Porter P., Carow CE., Firpo E., et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85 (1996) 733-744
6. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 (1996) 702-720
7. Bloom J., and Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13 (2003) 41-44
8. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3 (1997) 227-230
9. Kip1 expression in colorectal cancer: a clinico-pathological characterization. J. Pathol. 188 (1999) 18-23
10. Tsihlias J., Kapusta L.R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58 (1998) 542-548
11. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57 (1997) 3381-3385
12. Hwang C.F., Su C.Y., Huang S.C., Huang C.C., Fang F.M., Lui C.C., et al. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Lett. 189 (2003) 231-236
13. Ito Y., Matsuura N., Sakon M., Miyoshi E., Noda K., Takeda T., et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30 (1999) 90-99
14. Zerfass-Thome K., Zwerschke W., Mannhardt B., Tindle R., Botz J.W., and Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13 (1996) 2323-2330
15. Tae Kim Y., Kyoung Choi E., Hoon Cho N., Hung Ko J., Ick Yang W., Wook Kim J., et al. Expression of cyclin E and p27(KIP1) in cervical carcinoma. Cancer Lett. 153 (2000) 41-50
16. Cobb M.H., and Goldsmith E.J. How MAP kinases are regulated. J. Biol. Chem. 270 (1995) 14843-14846
17. Cano E., and Mahadevan L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20 (1995) 117-122
18. Crews C.M., Alessandrini A., and Erikson R.L. The primary structure of MEK. a protein kinase that phosphorylates the ERKSS gene product. Science 258 (1992) 478-480
19. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 (1995) 179-185
20. Hill C.S., and Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80 (1995) 199-211
21. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J. 9 (1995) 726-735
22. Marais R., Wynne J., and Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73 (1993) 381-393
23. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev., Cancer 4 (2004) 937-947
24. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., et al. Immunohistochemical demonstration of phosphor-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 8 (2002) 1168-1171
25. Mani A., and Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23 (2005) 4776-4789
26. Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I., and Takata T. High expression of S-phase kinase-interacting protein 2. human F-box protein. correlate with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61 (2001) 7044-7047
27. Latres E., Chiarle R., Schulman B.A., Pavletich N.P., Pellicer A., Inghirami G., et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2515-2520
28. Hershko D., Bornstein G., Ben-Izhak O., Carrano A., Pagano M., Krausz M.M., et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91 (2001) 1745-1751
29. Shapira M., Ben-Izhak O., Linn S., Futerman B., Minkov I., and Hershko DD. The prognostic impact of the ubiquitin ligase subunit Skp2 and Cks1 in colorectal carcinoma. Cancer 103 (2005) 1336-1346
30. Masuda T., Inoue H., Sonoda H., Mine S., Yoshikawa Y., Nakayama K., et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62 (2002) 3819-3825
31. Oliveira A.M., Okuno S.H., Nascimento A.G., and Lloyd R.V. Skp2 protein expression in soft tissue sarcomas. J. Clin. Oncol. 21 (2003) 722-727
32. Min Y.H., Cheong J.W., Lee M.H., Kim J.Y., Lee S.T., Hahn J.S., et al. Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis. Clin. Cancer Res. 10 (2004) 5123-5130
33. Radke S., Pirkmaier A., and Germain D. Differential expression of the F-box proteins SKP2 and SKP2B in breast cancer. Oncogene 24 (2005) 3448-3458
34. Shiozawa T., Shiohara S., Kanai M., Konishi I., Fujii S., and Nikaido T. Expression of the cell cycle regulator p27Kip1 in normal squamous epithelium. cervical intraepithelial neoplasia. and invasive squamous cell carcinoma of the uterine cervix. Cancer 92 (2001) 3005-3011
35. Cheung T.H., Lo K.W., Yu M.M., Yim S.F., Poon C.S., Chung T.K., et al. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett. 172 (2001) 93-98
36. Huang L.W., Chao S.L., Hwang J.L., and Chou Y.Y. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol. Oncol. 85 (2002) 524-528
37. Dowen S.E., Scott A., Mukher J.G., and Stanley M.A. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int. J. Cancer 105 (2003) 326-330
38. Yang G., Ayala G., De Marzo A., Tian W., Frolov A., Wheeler TM., et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 8 (2002) 3419-3426
39. Mammas I.N., Zafiropoulos A., Koumantakis E., Sifakis S., and Spandidos D.A. Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. Gynecol. Oncol. 92 (2004) 941-948
40. Adeyinka A., Nui Y., Cherlet T., Snell L., Watson PH., and Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res. 8 (2002) 1747-1753